What is the treatment for alcohol‑induced liver injury?

Treatment of Alcohol-Induced Liver Disease

Abstinence from alcohol is the single most important intervention that improves survival at all stages of alcohol-associated liver disease, and must be combined with multidisciplinary addiction management, nutritional support, and stage-specific medical therapy. 1

Core Treatment Pillars

1. Alcohol Abstinence and Addiction Management

All patients with alcohol-associated liver disease require mandatory referral to addiction specialists and treatment programs, particularly those with moderate to severe alcohol use disorder or clinically evident liver disease. 1

• Screen all patients using validated questionnaires (AUDIT-C ≥4, AUDIT >8, or binge drinking patterns) in primary care, gastroenterology clinics, emergency departments, and inpatient settings 1
• Offer brief intervention, pharmacotherapy, and referral to treatment for patients engaged in hazardous drinking 1
• Integrate alcohol use disorder treatment with medical care as this remains the best option for management of advanced liver disease, though evidence from randomized trials is limited 1

Pharmacotherapy for Alcohol Abstinence

Acamprosate is the preferred pharmacological agent for maintaining abstinence in patients with alcohol-associated liver disease due to its complete lack of hepatotoxicity and renal-only excretion. 1, 2

Acamprosate dosing:

• Patients ≥60 kg: 666 mg three times daily (1,998 mg/day total) 1, 2
• Patients <60 kg: Reduce dose by one-third to 1,332 mg/day 1, 2
• Initiate 3-7 days after last alcohol consumption once withdrawal symptoms have resolved 1, 2
• Treatment duration: 3-6 months typically, can extend to 12 months 1, 2
• Mechanism: Reduces withdrawal effects and craving for alcohol; desired concentration reached within 1-2 weeks 1

Critical caveat: Acamprosate is effective at maintaining abstinence, not inducing it—patients must be detoxified and abstinent before starting treatment, with number needed to treat of 12 to prevent relapse 2

Baclofen (GABA-B receptor agonist) is an alternative option:

• Effectively maintains abstinence by reducing alcohol craving in patients with liver cirrhosis 1
• Requires further confirmatory studies in this population 3

Naltrexone is contraindicated in patients with alcoholic liver disease due to hepatotoxicity concerns and risk of toxic liver injury 1, 2

Disulfiram should be avoided in severe alcoholic liver disease due to possible hepatotoxicity and poor tolerability 1, 2

Psychosocial Interventions

• Motivational interviewing for patients ambivalent about alcohol cessation 1
• Cognitive behavioral therapy, motivational enhancement therapy, and psychoeducation combined with pharmacotherapy 1
• Active involvement in group therapy such as Alcoholics Anonymous to reduce craving and maintain abstinence through peer support 1
• Family education and therapy as alcohol dependence is a dysfunctional family disorder requiring treatment of both patient and family members 1

2. Nutritional Support

All patients with alcoholic hepatitis or advanced liver disease should be assessed for protein-calorie malnutrition and vitamin/mineral deficiencies, with aggressive enteral nutritional therapy for severe disease. 1

• Protein-calorie malnutrition is common in alcohol-associated liver disease and associated with increased complications (infection, encephalopathy, ascites) and poor prognosis 1
• Severe disease requires aggressive enteral nutritional therapy 1
• Long-term aggressive nutritional therapy by enteral or oral route improves nutritional status in alcoholic cirrhosis 1

3. Stage-Specific Medical Therapy

For Severe Alcoholic Hepatitis (Maddrey Discriminant Function ≥32)

Risk stratification is essential: Calculate Maddrey Discriminant Function (MDF) and MELD score at presentation 1

Treatment algorithm for severe alcoholic hepatitis:

First-line therapy:

• Prednisolone 40 mg/day for 28 days (typically followed by discontinuation or 2-week taper) for patients without contraindications to steroids 1
• Contraindications include: active infection, gastrointestinal bleeding, renal failure, pancreatitis 1

Alternative therapy:

• Pentoxifylline 400 mg orally three times daily for 4 weeks if contraindications to steroids exist 1
• Pentoxifylline reduces mortality primarily by decreasing hepatorenal syndrome risk 1

Monitor response: Serial MELD score calculation and assessment for improvement in serum bilirubin or decline in MDF during first week of hospitalization 1

For Mild-Moderate Alcoholic Hepatitis (MDF <32)

• Close monitoring without specific medical interventions beyond nutritional support and abstinence 1
• These patients will likely not benefit from corticosteroids or pentoxifylline 1

4. Monitoring and Biomarkers

Alcohol biomarkers aid in diagnosis and support recovery:

• Phosphatidylethanol (PEth): Sensitivity 97-100%, specificity 66-96%, detection window 2-3 weeks, not affected by liver disease 1
• Urine ethyl glucuronide (EtG): Sensitivity 76-89%, specificity 93-99%, detection window 3 days 1
• Urine ethyl sulfate (EtS): Often used to confirm positive EtG, detection window 3 days 1

5. Long-Term Management

• Routine screening for cirrhosis complications in patients with alcoholic cirrhosis 4
• Timely referral to liver transplant program for decompensated cirrhosis 4
• Avoid pharmacologic therapies beyond those mentioned above, as other medications have shown no consistent benefit 4
• Continued abstinence reduces portal pressure, decreases progression to cirrhosis, and improves survival, though improvement may be less likely in female patients 1

Common Pitfalls

• Do not use naltrexone in patients with liver disease due to hepatotoxicity risk 1, 2
• Do not start acamprosate before withdrawal is complete and abstinence achieved 2
• Do not treat mild-moderate alcoholic hepatitis with corticosteroids or pentoxifylline—reserve for severe disease only 1
• Recidivism rates are 67-81% over one year—continuous addiction support is mandatory, not optional 1